Health Canada issued permission for a segment of doctors and therapists to implement magic mushrooms in their practices!
A mass destigmatizing of psychedelics is kicking off because companies like Delic (DELC) advocate for access to education on the benefits of managed psychedelic use. It’s exciting for me to see this company develop . . . and their stock prices along with them.
Global drug policy is changing. Psilocybin mushrooms and psychedelic therapies appear to be next in line for decriminalization, research, and sale. Delic’s goal is to educate and prepare investors for the psychedelic revolution that’s kicking off worldwide. This company is assembling a compelling drug development pipeline containing innovative treatments based on psychedelic substances. That development currently centers on psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative.
We need more companies willing to follow their lead.
Consider investing in Delic, even if you don’t regularly invest or invest in small amounts — it doesn’t need to be thousands of dollars. I can’t think of a cooler business to leap into this vertical with. They have a commitment to safety and educating the public about psychedelic treatments that’s impressive.
Delic has a Canadian ticker (CSE: DELC) and a U.S. ticker for OTC exchange (OTCQB: DELCF).
Disclaimer: This post exists for information and harm reduction purposes only. Note that the United Nations 1971 Convention on Psychotropic Substances deemed psilocybin a Schedule I substance, and it is illegal in most countries. The author of this blog does not condone the purchase, possession, sale, or consumption of any illegal substances.